Muhammad Rusli, Zulfikar Zulfikar, Santi Syafril


The most appropriate marker to assess the glucose level of diabetes mellitus patient with chronic kidney disease has not been recognized. The reduction of an erythrocyteslifetime will pull down the HbA1c from a patient with chronic kidney disease. Beside HbA1c, Glycated Albumin (GA) is an alternative glycemic marker. The aim of this study is to find out whether there is a comparison of HbA1c and glycated albumin levels in patients with type 2 DM with and without Chronic Kidney Disease (CKD). This research is an observational analytic study with a cross-sectional design. Conducted on 46 patients with DM type 2 with or without CKD at the Adam Malik Hospital, from August 2016 – December 2016 that fulfill the criteria, and after that, the HbA1c and GA were examined. The GA level in patients with DM type II and CKD (18.48±5.23)%, were not significantly different from those patient with DM type II without CKD (17.39±6.07)%. From the statistical test result, there is no significant difference of GA from patient with DM type II with CKD and without CKD (p=0.519)and so does the HbA1c levels in type 2 DM patients with CKD (8.1±1.74)% were lower than those patient with type 2 DM without CKD (8.6±1.67)% although there was no significant difference between  HbA1c level from patients with type 2 DM without CKD and with CKD (p=0.364) from the statistical test result. There is no significant difference between HbA1c level and glycated albumin from patients with DM type II with or without CKD.


Dm type 2, CKD, HbA1c, GA

Full Text:



ADA (American Diabetes Association), 2015, Standards for Medical Care in Diabetes, Diabetes Care, 38(Suppl 1) : S8-S16

ADA (American Diabetes Association), 2011, Standards for Medical Care in Diabetes, Diabetes Care, 34(Suppl 1) : S11-S61.

Suwitra, K. 2007. Penyakit Ginjal Kronik. Dalam: Sudoyo, A. W., Setiyohadi, B., Alwi, I., Simadibrata, M. K., Setiati, S. Buku Ajar Ilmu Penyakit Dalam. Jakarta: Pusat Penerbitan Dept. Ilmu Penyakit Dalam FK UI. 570-573.

Kemenkes RI. (2013). Buku Saku FAQ (Frequently Asked Questions) BPJS Kesehatan. Jakarta: Kementerian Kesehatan Republik Indonesia. Hal. 2 - 27.

Riset Kesehatan Dasar, 2013. Dalam : Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan Republik Indonesia tahun 2013, pp : 1 – 268.

Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200: 21-27.

Perkumpulan Endokrinologi Indonesia.Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2006. PB PERKENI, Jakarta 2006 : 1 – 47.

Okada T, Nakao T, Yamanaka T, Tamekuni T, Ikeda K. Influence of darbepoetin-α therapy on HbA1c values in hemodialysis patients. Clin Nephrol 72: 244-246, 2009.

Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, et al. A1c but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care; 2008; 31: 1945-1948

Takahasi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, et al. Comparison of Glycated Albumin (GA) and Glycated Hemoglobin (HbA1c) in Type 2 Diabetic Patients: Usefulness of GA for Evaluation of short-term Changes in Glycemic Control. Endocr. J. doi: 10.1507/endorj.K06-103.

SaishoY. Glycated albumin : Amore sensitive predictor of cardiovascular disease than glycated hemoglobin? Int J Diabetol & Vasc Dis Res 2013, I (6) : 1 – 3 62

Barry I. Freedman,1 Rajeev N.Comparison Of Glycated albumin And Hemoglobin A1c Concentration In Diabetic Subject On Peritoneal And Peritoneal And hemodialisis: Depart Of Internal Medicine, Pathology, Pediatric and Biostatistical Sciences, Winston- Salem, North , carolina, USA, vol 30. Pp 72-79

Powers AC. Diabetes mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison’s principles of internal medicine.17th edition. New York: McGraw Hill; 2008

Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909–913, 2001

Koga M, KasayamaS. Clinical impact of glycated albumin as another glycemic control maker. Endocrine J 2010 : 57 (9): 751 – 762

Kosecki SM, Rodgers PT, Adams MB: Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 39: 1557–1560, 2005

Peacock Tp, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Comparissonof glycated albumin and hemoglobin A1c level in diabetic subjects on hemodialysis. Kidne international 2008;25:1-7



  • There are currently no refbacks.